Finance outlook india logo
Home News Exclusive Expert's Viewpoint Corporate Startup Fintech Personal Magazine About Us Budget'26 Budget'24
  • Budget'25 Budget'24
    • Home
    • News
    Life Insurance Stocks Slump

    Life Insurance Stocks Slump; HDFC Life, SBI Life, and Max Financial Decline up to 7%


    Finance Outlook India Team | Thursday, 28 November 2024

    Life insurance company shares fell up to 7% on Thursday following reports that the Insurance Regulatory and Development Authority of India (IRDAI) may consider capping parent banks' share of insurers' total bancassurance business to up to 50%, according to CNBC-TV18, citing sources.

    Meanwhile, at the recently held State Bank of India (SBI) Economist Conclave, Finance Minister Nirmala Sitharaman stated that while bancassurance has increased insurance penetration, it has also resulted in mis-selling. Debasish Panda, chairman of the IRDAI, has expressed increased worry over banks misselling insurance products.

    In Thursday's intra-day trading on the BSE, shares of SBI Life Insurance (Rs 1,407.50) and Max Financial Services (Rs 1,100) fell 7%, while HDFC Life Insurance down 5.5 percent to Rs 643.50. At 02:14 pm, the BSE Sensex was down 1.53% at 79,003.

    52-week Highs

    SBI Life Insurance has fallen 27% from its 52-week high of Rs 1,935 set on September 3, 2024, as the insurer reported lower single-digit revenue growth in the September 2024 quarter (Q2FY25). According to data, Max Financial and HDFC Life are down 16% and 15% from their 52-week highs, respectively.

    However, in their October 2024 life insurance quarterly assessment, Elara Capital analysts reported stronger-than-expected annual premium equivalent (APE) growth for HDFC Life, ICICI Prudential, and Max Life. As a result, sector growth for H2FY25, which was forecast at 14% YoY, is expected to be revised higher assuming growth momentum continues.

    "Despite ongoing negotiations with distributors over commissions for non-linked savings products, October 2024 APE growth exceeded expectations," the brokerage business stated. Analysts predict total VNB growth of 8% YoY in H2FY25E, with lower VNB margins due to a higher ULIP mix. Lower VNB margins in FY25 are projected to have a negative impact on ROEV across companies. Furthermore, given the larger share of ULIP, which typically has weaker persistency, there may be negative operating variations in the embedded value (EV)," the analysts stated.



    Read More:

    ConvoZen Launches End-to-End Conversational AI

    India & France Revise Tax Treaty, Scrap MFN Clause, Ease Dividends

    KNOWLEDGE DECK

    Most Viewed

    • The Economic Impact of India-Pakistan War: A Detailed Analysis

    • Why Financial Literacy Matters More Than Ever for Today's Youth

    • Prominent Financial Advisors in India to Partner With

    • Rags to Riches: The Top 6 Indian Entrepreneurs' Motivational Tales of Success

    • Navigating Financial Disruption With Future Proof Financial Service Deliverability

    • India's Rs 31 Lakh Cr Green Push: Building the Foundation of a Net-Zero Future

    • Wakhariya & Wakhariya: Facilitating International Legal Processes across Diverse Domains

    • Aligning Financial Strategies with Sustainable Business Goals

    • The Top 5 Highest-paid Actors in India - 2024

    • Central Government Proposes Tax on Agricultural Water Usage

    • Carpediem Capital Invests INR 100 Crore, CorporatEdge to Deploy INR 350 Crore in the next 3 Years

    • EPFO Registers All-Time High Member Addition of 20.06 Lakh in May 2025

    • Unearthing Intricacies of Today and Beyond in the Indian Insurance Sector

    • Expected Correction in Housing Prices to Revive Sales in Coming Quarters

    • How to Choose the Right Mutual Fund for your Financial Goals?

    • Future of Corporate Finance: Emerging Trends in Treasury Solutions and Cash Management for MNCs

    • ElasticRun Announces FY24 Financial Results: Key Details

    • Financial Inclusion in Viksit Bharat

    • Abans Financial Services Advises Vaishali Pharma on Strategic Acquisition of Kesar Pharma






    🍪 Do you like Cookies?

    We use cookies to ensure you get the best experience on our website. Read more...

    Copyright © 2026 Finance Outlook India. All rights reserved.   Privacy Policy Terms of Use Blogs Conferences Subscribe WRAPUP’25